컨텐츠 바로가기

12.23 (월)

GC Group's 3 generations making their presence felt...'uncle-nephew' is gone, 'cousin management' is coming

댓글 첫 댓글을 작성해보세요
주소복사가 완료되었습니다

Heo Il-seop, GC Group Chairman's Eldest Son, Promoted to CFO after 8 Years

Signs of Change in Management System from Uncle and Nephew to Owner's Third-Generation Cousin

"It Seems Like 'Beautiful Management' Will Continue Even Under Cousin Management System"

한국금융신문

GC Green Cross office building./Photo=GC Green Cross


[Korea Financial Times, Kim Nayoung] GC Green Cross Group (GC Group) is in the mood to switch from the 'uncle-nephew' system that has been in place for about 10 years to 'cousin management'.

According to the pharmaceutical industry on the 23rd, the Green Cross Group is recently starting the 'owner's third generation' management in earnest through the regular executive personnel reshuffle in 2025. This is because GC Group Chairman Heo Il-seop's eldest son, Heo Jin-seong, in charge of GC Strategy 1, has been promoted to the head of the business management headquarters (executive director). He was appointed as the chief financial officer (CFO) of the holding company, GC Green Cross Holdings, changing his position from strategy to finance. It has been eight years since a member of the GC Group's owner family was promoted.

Executive director, Heo Jin-seong will be responsible for the overall management of the group, including not only accounting, but also investment, financing, and M&A.

There are voices in the industry saying that this personnel change is the beginning for GC Group's management succession. The current GC Group is jointly managed by an uncle and nephew. After the passing of GC Group Chairman Heo Young-seop in 2009, GC Holdings has been led by his younger brother, Chairman Heo Il-seop.

In 2015, the second son of former Chairman Heo Young-seop, Heo Eun-cheol, became the CEO of GC Green Cross, a key affiliate, and the uncle-nephew joint management began. Then, in 2017, former Chairman Heo’s third son, Heo Yong-jun, also entered the board of directors of Green Cross Holdings and became co-CEO with his uncle, Chairman Heo Il-seop.

There had been many speculations that if Chairman Heo Il-seop stepped down from management, the management of the brothers would begin, but the emergence of new headquarters director Heo Jin-seong has given strength to the possibility of cousin management. In particular, as the head of the management headquarters, which Executive Director Heo Jin-seong took on, was a key position that President Heo Yong-jun held just before he became CEO, Executive Director Heo Jin-seong could succeed Chairman Heo Il-seop in the future. Chairman Heo Il-seop was born in 1954, so it would not be strange for him to be considering succession.

In addition, Chairman Huh Il-seop's second son, Huh Jin-hoon, is also working as the head of the Aliglo team at the Global Business Headquarters at GC Green cross. He is in charge of the global business of 'Aliglo', an immunoglobulin product that has emerged as GC Green Cross's next-generation growth engine. However, he was born in 1991, so he is different in job title from other third-generation members born in the 1970s and 1980s.

Looking at the shareholding structure, all four third-generation owners have a strong presence. Chairman Huh Il-seop is the largest shareholder of Green Cross Holdings, holding 12.20%. He is followed by ▲President Huh Yong-joon with 2.91%, ▲President Huh Eun-cheol with 2.63%, ▲Executive Director Huh Jin-seong with 0.77%, and ▲ Huh Jin-hoon with 0.72%. Although Chairman He's eldest and youngest sons have lower stakes than their cousins, but that could change depending on how Mr. He handles his stake in the future.

Some in the market are speculating that the cousins may compete for shares in the future. However, the prevailing opinion is that GC Group will continue to show the same stability it has shown in its uncle-nephew management for more than a decade.

An industry insider explained, “The pharmaceutical industry calls GC Group ‘beautiful management’,” and “The pharmaceutical industry is an industry dominated by owner management, so there is a certain amount of management dispute, but GC Group, on the contrary, is showing balanced joint management.” He added, “Even if the system changes to cousin management, it will show the same beautiful management as it does now.”

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)


데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com
기사가 속한 카테고리는 언론사가 분류합니다.
언론사는 한 기사를 두 개 이상의 카테고리로 분류할 수 있습니다.